WallStSmart

AbbVie Inc (ABBV)vsPrologis Inc (PLD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 570% more annual revenue ($62.82B vs $9.38B). PLD leads profitability with a 39.7% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. PLD earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

PLD

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-20.5%)

Margin of Safety

-20.5%

Fair Value

$168.19

Current Price

$201.55

$33.36 premium

UndervaluedFair: $168.19Overvalued
PLDUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$267.33

Current Price

$144.09

$123.24 discount

UndervaluedFair: $267.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.3/10
Market CapQuality
$358.55B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

PLD6 strengths · Avg: 9.2/10
Profit MarginProfitability
39.7%10/10

Keeps 40 of every $100 in revenue as profit

Operating MarginProfitability
38.5%10/10

Strong operational efficiency at 38.5%

EPS GrowthGrowth
65.2%10/10

Earnings expanding 65.2% YoY

Market CapQuality
$132.66B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.14B8/10

Generating 1.1B in free cash flow

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
98.9x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.8%2/10

Earnings declined 45.8%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

PLD3 concerns · Avg: 3.0/10
P/E RatioValuation
35.8x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
6.8%3/10

ROE of 6.8% — below average capital efficiency

PEG RatioValuation
109.122/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : PLD

The strongest argument for PLD centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 39.7% and operating margin at 38.5%.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.

Bear Case : PLD

The primary concerns for PLD are P/E Ratio, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

ABBV profiles as a value stock while PLD is a mature play — different risk/reward profiles.

PLD carries more volatility with a beta of 1.35 — expect wider price swings.

ABBV is growing revenue faster at 12.4% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (63/100 vs 63/100) and 12.4% revenue growth. PLD offers better value entry with a 46.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Prologis Inc

REAL ESTATE · REIT - INDUSTRIAL · USA

Prologis, Inc. is a real estate investment trust headquartered in San Francisco, California that invests in logistics facilities, with a focus on the consumption side of the global supply chain.

Want to dig deeper into these stocks?